2026 update of the multisociety European guidelines on relapsing, metastatic hormone-sensitive and castration-resistant prostate cancer, based on 2023–2025 literature, covering ARPIs, metastasis-directed therapy, PARP inhibitors and PSMA-based therapy.
Guideline
Tilki et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer